{"id":956451,"date":"2026-04-30T07:19:43","date_gmt":"2026-04-30T11:19:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/"},"modified":"2026-04-30T07:19:43","modified_gmt":"2026-04-30T11:19:43","slug":"ac-immune-first-quarter-2026-financial-and-corporate-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/","title":{"rendered":"AC Immune First Quarter 2026 Financial and Corporate Updates"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <b>AC Immune First Quarter 2026 Financial and Corporate Updates<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD\/MAD results in healthy volunteers expected in H2 2026<\/li>\n<li style=\"margin-bottom:6pt\">Initiated final cohort, AD4, in ABATE Phase 1b\/2 trial of ACI-24 to treat Alzheimer&#8217;s Disease triggers milestone payment, <a href=\"https:\/\/ir.acimmune.com\/news\" rel=\"nofollow\" target=\"_blank\">as announced separately today<\/a><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Amended Morphomer<sup>\u00ae<\/sup> Tau collaboration with Lilly reflects growing excitement for targeting intracellular Tau and significant progress with our Morphomer<sup>\u00ae<\/sup> small molecules<\/li>\n<li style=\"margin-bottom:6pt\">Approaching multiple milestones including 12-month interim results of the AD3 cohort in ABATE in Q2 2026 and full data from Part 1 of ACI-7104 VacSYn Phase 2 trial expected in H2 2026<\/li>\n<li style=\"margin-bottom:6pt\">Cash resources of CHF 74.8 million as of March 31, 2026, provide funding into Q4 2027\n<\/li>\n<\/ul>\n<p>\n        <b>Lausanne, Switzerland, April 30, 2026 &#8212; <\/b>AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today provided financial and corporate updates for the quarter ended March 31, 2026.<\/p>\n<p>\n        <b>Dr. Andrea Pfeifer, CEO of AC Immune SA, commented:<\/b> \u201cThe progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our anti-Abeta active immunotherapy and Tau aggregation inhibitor small molecules, respectively. These have the potential to change the way we target the proteinopathies that drive Alzheimer\u2019s and other neurodegenerative diseases (NDDs). This is further exemplified by the presentation of the interim results for ACI-7104 at AD\/PD 2026 showing that our active immunotherapy targeting a-synuclein (a-syn) has the potential to modify disease pathology in Parkinson\u2019s disease (PD). We also advanced our NLRP3 inhibitor ACI-19764 into clinical development, further demonstrating the power of AC Immune\u2019s technology to target the key pathways that contribute to neurodegeneration.<\/p>\n<p>\u201cWe are now moving towards multiple value inflection points during 2026. These include Phase 2 data readouts on our active immunotherapies ACI-7104 and ACI-24, and initial results from the Phase 1 trial of ACI-19764 also anticipated this year.\u201d<\/p>\n<p>\n        <b>Q1 2026 and Subsequent Highlights:<\/b>\n      <\/p>\n<p>\n        <i>ACI-24 anti-Abeta active immunotherapy<\/i>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">As <a href=\"https:\/\/ir.acimmune.com\/news\" rel=\"nofollow\" target=\"_blank\">announced separately today<\/a>, AC Immune has initiated the final cohort, AD4, in the ongoing Phase 1b\/2 ABATE trial of ACI-24 to treat Alzheimer&#8217;s Disease<\/li>\n<li style=\"margin-bottom:6pt\">Treatment of the first patient in cohort AD4 triggers a $12 million milestone payment from Takeda<\/li>\n<\/ul>\n<p>\n        <i>Morphomer-Tau small molecule program<\/i>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-announces-amendment-morphomer-r-tau-license-and-0\" rel=\"nofollow\" target=\"_blank\">Amended agreement with Eli Lilly and Co.<\/a> (Lilly) reflects growing excitement for targeting intracellular Tau and significant progress with our Morphomer small molecules<\/li>\n<li style=\"margin-bottom:6pt\">The amendment continues the research and collaboration to cover development of new lead Tau Morphomer\u00ae candidates and potential back-up compounds.<\/li>\n<li style=\"margin-bottom:6pt\">Under this amendment, AC Immune receives a CHF10 million upfront payment (Q2 2026 event) and a subsequent milestone payment subject to Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for further development, regulatory and commercial milestones of over CHF1.7 billion, plus tiered percentage royalty payments in the low double digits, as previously disclosed.<\/li>\n<li style=\"margin-bottom:6pt\">Investigational New Drug (IND)-enabling studies are expected to be initiated imminently.<\/li>\n<\/ul>\n<p>\n        <i>ACI-7104, anti-a-syn active immunotherapy<\/i>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Presented updated interim results from Part 1 of the Phase 2 VacSYn clinical trial in early-stage Parkinson&#8217;s disease at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2026), including promising biomarker data.\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Interim results previously presented include changes in biomarkers and clinical measures all suggesting potential disease modification through treatment with ACI-7104<\/li>\n<li style=\"margin-bottom:6pt\">Final results for the week 104 full data set from Part 1 of the VacSYn trial expected to be reported in H2 2026.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n        <i>NLRP3 inhibitor, ACI-19764, small molecule program<\/i>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Dosed the <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-initiates-phase-1-clinical-trial-nlrp3-inhibitor\" rel=\"nofollow\" target=\"_blank\">first subjects in a Phase 1 clinical trial of ACI-19764<\/a>, a brain-penetrant Morphomer small molecule targeting the NLRP3 inflammasome.<\/li>\n<li style=\"margin-bottom:6pt\">Morphomer NLRP3 inhibitors have potential to intervene at the earliest stages of disease in neurodegenerative conditions, including AD, PD, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.<\/li>\n<li style=\"margin-bottom:6pt\">Potential additional indications include inflammatory disorders, cardiovascular disease, metabolic disorders, skin inflammatory diseases, and certain rare diseases, among others.\n<\/li>\n<\/ul>\n<p>\n        <i>ACI-35 (JNJ-2056) anti-pTau active immunotherapy<\/i>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">AC Immune\u2019s partner Janssen Pharmaceuticals, Inc. (Janssen), a Johnson &amp; Johnson company, is seeking a protocol amendment for the ReTain study to enable earlier insights into the biological activity of JNJ-2056 and its potential for clinical benefit. Submissions to all relevant health authorities are ongoing.<\/li>\n<li style=\"margin-bottom:6pt\">The study remains active, with enrollment paused, and there is no change for enrolled participants at this time.<\/li>\n<li style=\"margin-bottom:6pt\">The study is ongoing based on ~60 enrolled patients with a minimum of 12 months and up to 24 months of treatment and follow-up.\n<\/li>\n<\/ul>\n<p>\n        <i>TDP-43 PET tracer<\/i>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">\n          <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-presents-first-vivo-images-brain-tdp-43-pathology\" rel=\"nofollow\" target=\"_blank\">Presented <\/a>Phase 1 data including the first <i>in vivo<\/i> images of TDP-43 pathology in the human brain, detected using its first-in-class positron emission tomography (PET) tracer ACI-19626, at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Disease (AD\/PD\u2122 2026).<\/li>\n<li style=\"margin-bottom:6pt\">Initial Phase 1 data (PET scans) with ACI-19626 showed that tracer uptake was significantly higher in key regions of the brain in patients with frontotemporal dementia (FTD) and we are currently evaluating the tracer in ALS patients.<\/li>\n<li style=\"margin-bottom:6pt\">Clinical data indicate a pharmacokinetic (PK) profile suitable for human brain imaging and potentially pharmacodynamic analysis of therapeutics targeting TDP-43 pathology.\n<\/li>\n<\/ul>\n<p>\n        <i>AC Immune AD\/PD<\/i><br \/>\n        <sup><br \/>\n          <i>TM<\/i><br \/>\n        <\/sup><br \/>\n        <i> 2026 symposium<\/i>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Hosted an <a href=\"https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immune-announces-upcoming-industry-symposium-parkinsons\" rel=\"nofollow\" target=\"_blank\">industry symposium<\/a> on achieving precision prevention in Parkinson\u2019s disease, highlighting Phase 2 clinical data on our ACI-7104 active immunotherapy, our small molecule programs targeting intracellular alpha-synuclein, and innovative diagnostic approaches to identifying at-risk individuals.\n<\/li>\n<\/ul>\n<p>\n        <b>Anticipated 2026 Milestones<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Program<\/b>\n          <\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Milestone<\/b>\n          <\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Expected in<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ACI-7104.056<br \/>anti-a-syn active immunotherapy<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Final data from Part 1 of the Phase 2 VacSYn trial in PD<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ACI-24.060<br \/>anti-Abeta active immunotherapy<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Interim results from ABATE Phase 2 trial after reaching 12-month treatment timepoint in the AD3 cohort<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H1 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ACI-19764<br \/>NLRP3 inhibitor<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Results from Phase 1 trial in healthy volunteers<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Morphomer-Tau aggregation inhibitors<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Initiation of IND-enabling studies<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H1 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Morphomer a-syn aggregation inhibitor<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Lead declaration<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H1 2026<\/td>\n<\/tr>\n<\/table>\n<p>\n        <b><br \/>\n          <br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>Analysis of Financial Statements for the Quarter Ended March 31, 2026<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">\n          <b>Cash Position:<\/b> The Company had total cash resources of CHF 74.8 million (CHF 91.4 million as of December 31, 2025), composed of CHF 19.2 million in cash and cash equivalents and CHF 55.6 million in short-term financial assets. The Company\u2019s cash resources are expected to provide sufficient capital to last into Q4 2027, excluding potential milestone payments.<\/li>\n<li style=\"margin-bottom:6pt\">\n          <b>R&amp;D expenditures:<\/b> R&amp;D expenses for the three months ended March 31, 2026, were CHF 11.8 million, compared with CHF 15.9 million for the comparable period in 2025. The decrease was partly due to lower personnel and operational spend of approximately CHF 1.7 million as a result of our pipeline focus initiatives announced in Q3 2025, as well as lower spend associated with our active immunotherapy programs, particularly in the upfront CMC costs prior to initiation of phase 2 studies.<\/li>\n<li style=\"margin-bottom:6pt\">\n          <b>G&amp;A expenditures:<\/b> G&amp;A expenses in the period were CHF 4.2 million in the period ended March 31, 2026, compared to CHF 4.4 million for same period in 2025.<\/li>\n<li style=\"margin-bottom:6pt\">\n          <b>Financial result:<\/b> The financial result was a loss of less than CHF 0.1 million for the period, compared with a gain of CHF 0.3 million for the comparable period. The change was primarily driven by a decrease in interest income earned on short-term financial assets, partially offset by lower foreign exchange losses.<\/li>\n<li style=\"margin-bottom:6pt\">\n          <b>IFRS loss for the period<\/b>: The Company had a net loss of CHF 14.8 million for the period ended March 31, 2026, compared to CHF 19.0 million for the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n<p>\n        <b>About\u00a0AC Immune SA\u00a0<\/b>\n      <\/p>\n<p>AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen\u00ae and Morphomer\u00ae, fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$4.5 billion in potential milestone payments plus royalties.<\/p>\n<p>SupraAntigen\u00ae is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer\u00ae is a registered trademark of AC Immune SA in CA, CN, CH, EU, GB, JP, KR, NO, RU and SG.<\/p>\n<p>The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.<\/p>\n<p>\n        <b>For further information, please contact:<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:490pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:341.28125px;vertical-align: top\">\n            <b>SVP,\u00a0Investor Relations\u00a0&amp; Corporate Communications<\/b><\/p>\n<p>Gary Waanders, Ph.D., MBA<br \/>AC Immune<br \/>Phone: +41 21 345 91 91<br \/>Email:\u00a0<a href=\"mailto:gary.waanders@cimmune.com\" rel=\"nofollow\" target=\"_blank\">gary.waanders@acimmune.com<\/a><\/p>\n<\/td>\n<td style=\"width:283.5px;vertical-align: top\">\n<p>            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:341.28125px;vertical-align: top\">\n            <b>International Media<\/b><\/p>\n<p>Chris Maggos<br \/>Cohesion Bureau<br \/>Phone: +41 79 367 6254<br \/>Email:\u00a0<a href=\"mailto:chris.maggos@cohesionbureau.com\" rel=\"nofollow\" target=\"_blank\">chris.maggos@cohesionbureau.com<\/a><\/td>\n<td style=\"width:283.5px;vertical-align: top\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <b>Forward looking statements<\/b>\n      <\/p>\n<p>This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n<p align=\"center\">\n        <b>Condensed Consolidated Balance Sheets (Unaudited)<\/b><br \/>\n        <br \/>\n        <b>(In CHF thousands)<\/b>\n      <\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:92.58%;border-collapse:collapse\">\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:12.94%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>As\u00a0of<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>March\u00a031,\u00a0<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>December\u00a031,\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>\u00a0\u00a0\u00a0\u00a0<\/b>\n          <\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>\u00a0\u00a0\u00a0\u00a0<\/b>\n          <\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>2026<\/b>\n          <\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>\u00a0\u00a0\u00a0\u00a0<\/b>\n          <\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Assets<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>\u00a0\u00a0<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>\u00a0\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Non-current assets<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Property, plant and equipment<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,057<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,989<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Right-of-use assets<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,310<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,540<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Intangible asset<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">50,416<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">50,416<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Long-term financial assets<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">585<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">584<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total non-current assets<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">57,368<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">57,529<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Current assets<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Prepaid expenses<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,744<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,972<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Accrued income<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">230<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">360<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Other current receivables<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,282<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">978<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Short-term financial assets<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">55,628<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">64,617<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Cash and cash equivalents<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">19,169<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">26,795<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total current assets<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">80,053<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">96,722<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total assets <\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">137,421<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">154,251<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Shareholders&#8217; equity and liabilities<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Shareholders\u2019 equity<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Share capital<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,257<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,253<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Share premium<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">482,345<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">481,863<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Treasury shares<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">(218)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">(218)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Currency translation differences<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">7<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">7<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Accumulated losses<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(452,857)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(439,021)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total shareholders\u2019 equity<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">31,534<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">44,884<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Non-current liabilities<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Long-term deferred contract revenue<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,292<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,339<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Long-term lease liabilities<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,479<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,689<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Net employee defined benefit liabilities<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">8,868<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">8,646<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total non-current liabilities<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">13,639<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">14,674<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Current liabilities<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Trade and other payables<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,319<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,068<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Accrued expenses<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">6,469<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">8,067<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Short-term deferred contract revenue<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">83,635<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">83,706<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Short-term lease liabilities<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">825<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">852<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total current liabilities<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">92,248<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">94,693<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total liabilities<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">105,887<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">109,367<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total shareholders\u2019 equity and liabilities<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">137,421<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">154,251<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        \n      <\/p>\n<p align=\"center\">\n        <b>Condensed Consolidated Statements of Income\/(Loss) (Unaudited)<\/b><br \/>\n        <br \/>\n        <b>(In CHF thousands, except for per-share data)<\/b>\n      <\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:92.58%;border-collapse:collapse\">\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:12.94%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>For the Three Months<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:12.94%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>Ended March\u00a031,\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>2026<\/b>\n          <\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Revenue<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\n            <b>\u00a0\u00a0\u00a0\u00a0<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\n            <b>\u00a0\u00a0\u00a0\u00a0<\/b>\n          <\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>\u00a0\u00a0<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\n            <b>\u00a0\u00a0\u00a0\u00a0<\/b>\n          <\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <b>\u00a0\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Contract revenue<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,119<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">990<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total revenue<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,119<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">990<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Operating expenses<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\n            <b>\u00a0<\/b>\n          <\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Research &amp; development expenses<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">(11,744)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">(15,916)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">General &amp; administrative expenses<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">(4,174)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">(4,443)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Other operating income\/(expense), net<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">11<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(1)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Total operating expenses<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(15,907)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(20,360)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Operating loss<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(14,788)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,370)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Financial income<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">228<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">687<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Financial expense<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">(65)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">(54)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Exchange differences<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(176)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(292)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Finance result, net<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(13)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">341<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Loss before tax<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(14,801)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,029)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Income tax expense<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\n            <b>Loss for the period<\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(14,801)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,029)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Loss per share:<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.48%;vertical-align: bottom\">Basic and diluted loss per share for the period attributable to equity holders<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.15)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.19)<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        \n      <\/p>\n<p align=\"center\">\n        <b>Condensed Consolidated Statements of Comprehensive Income\/(Loss) (Unaudited)<\/b><br \/>\n        <br \/>\n        <b>(In CHF thousands)<\/b>\n      <\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:92.58%;border-collapse:collapse\">\n<tr>\n<td style=\"width:34.47%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.47%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:12.94%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>For the Three Months<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.47%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:12.94%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>ended March\u00a031,\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.47%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0\u00a0\u00a0<\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0\u00a0\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>2026<\/b>\n          <\/td>\n<td style=\"width:1.29%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0\u00a0\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <b>2025<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.47%;vertical-align: bottom\">Loss for the period<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">(14,801)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,029)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.47%;vertical-align: bottom\">Items that will be reclassified to income or loss in subsequent periods (net of tax):<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.47%;vertical-align: bottom\">Currency translation differences<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">4<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.47%;vertical-align: bottom\">Other comprehensive income\/(loss)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">4<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.47%;vertical-align: bottom\">\n            <b>Total comprehensive loss, net of tax <\/b>\n          <\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.83%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(14,801)<\/td>\n<td style=\"width:1.29%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:5.82%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,025)<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/1423053a-ff8f-413e-9dd7-b1ac505ed625\">20260429__ACIU Q1 2026 Update-final<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/Mjc1NjYwNWMtZGUwNy00Y2RhLWE3YzYtNTIzOTc0MmM3MTg0LTEwMzc0NDMtMjAyNi0wNC0zMC1lbg==\/tiny\/AC-Immune-SA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD\/MAD results in healthy volunteers expected in H2 2026 Initiated final cohort, AD4, in ABATE Phase 1b\/2 trial of ACI-24 to treat Alzheimer&#8217;s Disease triggers milestone payment, as announced separately today Amended Morphomer\u00ae Tau collaboration with Lilly reflects growing excitement for targeting intracellular Tau and significant progress with our Morphomer\u00ae small molecules Approaching multiple milestones including 12-month interim results of the AD3 cohort in ABATE in Q2 2026 and full data from Part 1 of ACI-7104 VacSYn Phase 2 trial expected in H2 2026 Cash resources of CHF 74.8 million as of March 31, 2026, provide &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AC Immune First Quarter 2026 Financial and Corporate Updates&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-956451","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune First Quarter 2026 Financial and Corporate Updates - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune First Quarter 2026 Financial and Corporate Updates - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD\/MAD results in healthy volunteers expected in H2 2026 Initiated final cohort, AD4, in ABATE Phase 1b\/2 trial of ACI-24 to treat Alzheimer&#8217;s Disease triggers milestone payment, as announced separately today Amended Morphomer\u00ae Tau collaboration with Lilly reflects growing excitement for targeting intracellular Tau and significant progress with our Morphomer\u00ae small molecules Approaching multiple milestones including 12-month interim results of the AD3 cohort in ABATE in Q2 2026 and full data from Part 1 of ACI-7104 VacSYn Phase 2 trial expected in H2 2026 Cash resources of CHF 74.8 million as of March 31, 2026, provide &hellip; Continue reading &quot;AC Immune First Quarter 2026 Financial and Corporate Updates&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T11:19:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune First Quarter 2026 Financial and Corporate Updates\",\"datePublished\":\"2026-04-30T11:19:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/\"},\"wordCount\":1832,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/\",\"name\":\"AC Immune First Quarter 2026 Financial and Corporate Updates - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==\",\"datePublished\":\"2026-04-30T11:19:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-first-quarter-2026-financial-and-corporate-updates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune First Quarter 2026 Financial and Corporate Updates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune First Quarter 2026 Financial and Corporate Updates - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune First Quarter 2026 Financial and Corporate Updates - Market Newsdesk","og_description":"AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD\/MAD results in healthy volunteers expected in H2 2026 Initiated final cohort, AD4, in ABATE Phase 1b\/2 trial of ACI-24 to treat Alzheimer&#8217;s Disease triggers milestone payment, as announced separately today Amended Morphomer\u00ae Tau collaboration with Lilly reflects growing excitement for targeting intracellular Tau and significant progress with our Morphomer\u00ae small molecules Approaching multiple milestones including 12-month interim results of the AD3 cohort in ABATE in Q2 2026 and full data from Part 1 of ACI-7104 VacSYn Phase 2 trial expected in H2 2026 Cash resources of CHF 74.8 million as of March 31, 2026, provide &hellip; Continue reading \"AC Immune First Quarter 2026 Financial and Corporate Updates\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-30T11:19:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune First Quarter 2026 Financial and Corporate Updates","datePublished":"2026-04-30T11:19:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/"},"wordCount":1832,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/","name":"AC Immune First Quarter 2026 Financial and Corporate Updates - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==","datePublished":"2026-04-30T11:19:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3OTAzNyM0MDIzODM5OTMjMjAyNTg3MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-first-quarter-2026-financial-and-corporate-updates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune First Quarter 2026 Financial and Corporate Updates"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=956451"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956451\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=956451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=956451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=956451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}